Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genentech buys Tanox for $905mm in cash

Executive Summary

Genentech has agreed to buy Tanox, a company that discovers and develops monoclonal antibody therapeutics for inflammation, cancer, infectious diseases, and autoimmune and respiratory disorders, for $20 per share in cash (a 46% premium) for a total of $905mm--more than 20 times its 2005 sales.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register